Filtered By:
Condition: Thrombosis
Drug: Activase
This page shows you your search results in order of relevance. This is page number 8.
Order by Relevance | Date
Total 351 results found since Jan 2013.
"Fou Rire Prodromique" as the Presentation of a Left Frontal Ischemic Stroke (P02.040)
CONCLUSIONS: Frontal lobe involvement affecting the Broca's area, as we described in our case, has only been described once. We conclude that the patient's laughter attack was the initial manifestation of the stroke suggesting that an acute infarct of Broca's area is capable of producing this unusual clinical presentation.Disclosure: Dr. Rosales has nothing to disclose. Dr. Garcia-Gracia has nothing to disclose. Dr. Salgado has received personal compensation in an editorial capacity from Belvoir Media Group as Consulting Editor of A Special Report published by the editors of Heart Advisor Cleveland Clinic STROKE: Advances ...
Source: Neurology - February 14, 2013 Category: Neurology Authors: Rosales, D., Garcia-Gracia, C., Salgado, E. Tags: P02 Cerebrovascular Disease II Source Type: research
Time to Blood Pressure Control Before Thrombolytic Therapy in Patients With Acute Ischemic Stroke: Comparison of Labetalol, Nicardipine, and Hydralazine
Conclusions: Adequate initial dosing of antihypertensive treatment has the potential to reduce time to blood pressure control and possibly time to alteplase therapy. The optimal antihypertensive regimen for controlling blood pressure before alteplase therapy remains unclear.
Source: Journal of Neuroscience Nursing - November 5, 2015 Category: Neuroscience Tags: Pharmacology Update Source Type: research
Are all stroke patients eligible for fast alteplase treatment? An analysis of unavoidable delays.
CONCLUSIONS: Up to 31% of patients have delays due to medical or eligibility-related causes that may be legitimate reasons for providing alteplase later than the benchmark time of 60 minutes. This article is protected by copyright. All rights reserved.
PMID: 26824684 [PubMed - as supplied by publisher]
Source: Accident and Emergency Nursing - January 29, 2016 Category: Emergency Medicine Authors: Choi PM, Desai JA, Kashyap D, Stephenson C, Kamal N, Vogt S, Bohm V, Suddes M, Bugbee E, Hill MD, Demchuk AM, Smith EE Tags: Acad Emerg Med Source Type: research
Thrombolysis and Thrombectomy for Acute Ischemic Stroke: Strengths and Synergies
Semin Thromb HemostDOI: 10.1055/s-0036-1585078Acute ischemic stroke is responsible for around 80% of all strokes and is a leading cause of disability and death globally. There are two potential treatment strategies: restoring blood flow (reperfusion) and preventing cellular injury (neuroprotection). As yet, all the successful trials have involved reperfusion with numerous failures of neuroprotectants. There are two proven reperfusion strategies. Intravenous thrombolysis with alteplase was first demonstrated to reduce disability with publication of the National Institute of Neurological Disorders and Stroke tissue plasminog...
Source: Seminars in Thrombosis and Hemostasis - July 28, 2016 Category: Hematology Authors: Campbell, Bruce C. V. Tags: Review Article Source Type: research
Treatment With Intravenous Alteplase for Acute Ischemic Stroke After Reversal of Dabigatran With Idarucizumab: A Case Study
Treatment options for anticoagulated patients presenting with ischemic stroke are limited. Off-label use of idarucizumab to rapidly reverse the anticoagulant effect of dabigatran may ensure eligibility for thrombolytic therapy with alteplase. This case describes a 77-year-old white male who presented to the hospital 89 minutes after sudden onset of right-sided hemiparesis, dysarthria, and facial palsy. Significant history included atrial fibrillation and previous right-sided cortical stroke. Medication reconciliation revealed he was taking dabigatran 150 mg twice a day, with the last dose being 179 minutes before presentat...
Source: Journal of Neuroscience Nursing - January 8, 2019 Category: Neuroscience Tags: Case Study Source Type: research
Using Tenecteplase for Acute Ischemic Stroke: What Is the Hold Up?
Alteplase is the only Food and Drug Administration-approved intravenous (IV) thrombolytic medication for acute ischemic stroke. However, multiple recent studies comparing tenecteplase and alteplase suggest that tenecteplase is at least as efficacious as alteplase with regards to neurologic improvement. When given at 0.25 milligrams per kilogram (mg/kg), tenecteplase may have less bleeding complications than alteplase as well. This narrative review evaluates the literature and addresses the practical issues with regards to the use of tenecteplase versus alteplase for acute ischemic stroke, and it recommends that physicians ...
Source: Western Journal of Emergency Medicine - February 24, 2020 Category: Emergency Medicine Source Type: research
Tenecteplase for Acute Ischemic Stroke Treatment
Semin Neurol DOI: 10.1055/s-0040-1722722The introduction of thrombolytic therapy in the 1990s has transformed acute ischemic stroke treatment. Thus far, intravenous recombinant tissue plasminogen activator (rt-PA) also known as alteplase is the only thrombolytic proven to be efficacious and approved by the United States Food and Drug Administration. But the thrombolytic agent tenecteplase (TNK) is emerging as a potential replacement for rt-PA. TNK has greater fibrin specificity, slower clearance, and higher resistance to plasminogen activator inhibitor-1 than rt-PA. Hence, TNK has the potential to provide superior lysis wi...
Source: Seminars in Neurology - January 20, 2021 Category: Neurology Authors: Baird, Alison E. Jackson, Richard Jin, Weijun Tags: Review Article Source Type: research
Intravenous Alteplase at 0.6 mg/kg for Unknown Onset Stroke with Prior Antithrombotic Medication: THAWS Randomized Clinical Trial
CONCLUSION: Alteplase appears more beneficial in patients with prior antithrombotic medication.PMID:35197420 | DOI:10.5551/jat.63337
Source: Journal of Atherosclerosis and Thrombosis - February 24, 2022 Category: Cardiology Authors: Masatoshi Koga Manabu Inoue Kaori Miwa Sohei Yoshimura Mayumi Fukuda-Doi Junya Aoki Koko Asakura Takao Kanzawa Masafumi Ohtaki Kenji Kamiyama Yusuke Yakushiji Shuichi Igarashi Ryosuke Doijiri Yasuhiro Ito Yasushi Takagi Makoto Sasaki Takanari Kitazono Kaz Source Type: research
Advances in Acute Ischemic Stroke Therapy
Circ Res. 2022 Apr 15;130(8):1230-1251. doi: 10.1161/CIRCRESAHA.121.319948. Epub 2022 Apr 14.ABSTRACTThe treatment of acute ischemic stroke continues to advance. The mainstay of treatment remains intravenous thrombolysis with alteplase. Recent studies demonstrated that later treatment with alteplase is beneficial in patients selected with advanced imaging techniques. Tenecteplase has been evaluated as an alternative thrombolytic drug and evidence suggests that it is as least as effective as alteplase and may lyse large vessel clots more effectively. Endovascular therapy with mechanical thrombectomy has now been shown to be...
Source: Circulation Research - April 14, 2022 Category: Cardiology Authors: Yunyun Xiong Ajay K Wakhloo Marc Fisher Source Type: research
